Immunocore Holdings Plc (IMCR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Immunocore Holdings' CFO Travis Coy outlined the company's strategy at the Morgan Stanley Global Healthcare Conference, emphasizing the strong performance of its approved TCR therapy, KIMMTRAK, which generated $192 million in H1 despite expected growth moderation in its current indication. Significant future growth is anticipated from KIMMTRAK's Phase III expansions into advanced cutaneous melanoma (data H2 next year) and adjuvant uveal melanoma, which could substantially broaden its addressable patient population. The company is also advancing its PRAME portfolio, including a Phase III in first-line cutaneous melanoma, and early-stage autoimmune and infectious disease programs, all supported by its innovative TCR platform, AI integration, and a robust balance sheet with nearly $900 million in cash, enabling sustained pipeline investment.

Analysis

Immunocore's financial and strategic position is underpinned by the strong commercial performance of KIMMTRAK, its approved T-cell receptor (TCR) therapy for metastatic uveal melanoma. The product generated $192 million in the first half of the year, representing 32% year-over-year growth, and has achieved approximately 70% market penetration in the U.S. While management guides for a moderation of this growth rate from the recent 4-7% quarterly sequential pace as the launch matures, the product's profile is bolstered by real-world data showing a 13-14 month duration of therapy, exceeding the 10-11 months observed in clinical trials. The primary value inflection for KIMMTRAK now lies in its two Phase III life-cycle expansion trials. The TEBE-AM study in advanced cutaneous melanoma, with data anticipated in the second half of 2026, could add 2,000 to 4,000 patients to its addressable market, a significant increase over the current 1,000. Beyond KIMMTRAK, the company is advancing a deep pipeline, including a second late-stage asset, brenetafusp, in a Phase III trial for frontline cutaneous melanoma. Further diversification is evident in early-stage programs for infectious diseases, with HBV data expected in November, and autoimmune diseases, demonstrating the modularity of its TCR platform. This expansive R&D effort, which includes three ongoing Phase III studies, is fully funded by a robust balance sheet featuring nearly $900 million in cash, mitigating near-term financing risk and providing strategic flexibility for in-licensing opportunities.

Key Decisions for Investors

• Investors should monitor KIMMTRAK's sequential growth for the expected moderation in its current indication, while focusing on the far more significant value driver of its pipeline catalysts.
• The primary catalyst to watch is the Phase III TEBE-AM data in advanced cutaneous melanoma, expected in H2 2026, which could significantly re-accelerate revenue growth by more than doubling KIMMTRAK's addressable patient population.
• The company's strong balance sheet, with nearly $900 million in cash, de-risks the execution of its multiple late-stage trials and provides optionality for strategic business development, making financing concerns a low near-term risk.
• Consider the long-term value of platform diversification, with upcoming single ascending dose data for the HBV program in November offering the first clinical test for the company's infectious disease franchise.